8-KEarnings & ResultsOther EventsExhibits & Filings

BIOGEN INC. 8-K Report, Financial Results (Oct 21, 2020)

Filed October 21, 2020For Securities:BIIB

Summary

Biogen Inc. (BIIB) filed an 8-K on October 21, 2020, announcing its third-quarter 2020 financial results and a new $5.0 billion share repurchase program. The press release detailing the financial performance is furnished as an exhibit, providing investors with recent operational and financial condition updates. Investors should refer to this press release for specific financial metrics, revenue figures, and profitability details for the quarter ended September 30, 2020. In addition to the quarterly results, Biogen's Board of Directors authorized a significant "2020 Share Repurchase Program" to buy back up to $5.0 billion of the company's common stock. This program, which has no expiration date, signals management's confidence in the company's value and is designed to return capital to shareholders. The repurchased shares will be retired, which can positively impact earnings per share metrics over time.

Key Highlights

  • 1Biogen announced third-quarter 2020 financial results on October 21, 2020, via a press release furnished with this 8-K filing.
  • 2A new "2020 Share Repurchase Program" was authorized by the Board of Directors.
  • 3The share repurchase program allows for the buyback of up to $5.0 billion of Biogen's common stock.
  • 4The 2020 Share Repurchase Program does not have a specified expiration date.
  • 5All shares repurchased under the new program will be retired.
  • 6The press release containing the financial results is incorporated by reference but is not deemed 'filed' under Section 18 of the Exchange Act.

Frequently Asked Questions

The 8-K filing itself does not detail the Q3 2020 financial results; instead, it references a press release (Exhibit 99.1) furnished on October 21, 2020. Investors need to review this press release for specific figures related to revenue, profitability, and other key financial performance indicators for the third quarter of 2020.

The $5.0 billion share repurchase program indicates that Biogen's management believes the company's stock is undervalued and aims to return capital to shareholders. The absence of an expiration date suggests a potentially long-term commitment to share buybacks. Retiring repurchased shares can also lead to an increase in earnings per share (EPS) by reducing the number of outstanding shares.

No, the press release announcing the third-quarter results is furnished under Item 2.02 and is specifically stated not to be 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934. This means Biogen is not subject to the liabilities under that section for the information contained within the press release, though it is still considered important information for investors.